Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05860114
Other study ID # ITF/2357/55 - PART 3
Secondary ID 2021-005756-11
Status Completed
Phase Phase 1
First received
Last updated
Start date March 21, 2022
Est. completion date May 24, 2022

Study information

Verified date May 2023
Source Italfarmaco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary objective: To evaluate the plasma and urine PK of givinostat following multiple oral doses of givinostat. Secondary objective: To assess the safety and tolerability multiple oral doses of givinostat.


Description:

This study was planned as a phase I, open-label, 3-part, fixed-sequence, nonrandomized study in healthy male and female subjects. The study (Part 3) aimed at assessing Givinostat and its metabolites (ITF2374, ITF2375, ITF2440 and ITF2563) plasma and urine concentrations and thereof derived pharmacokinetic parameters following single oral dose administration of givinostat (day 1) and following multiple oral dose administration of givinostat (day 5 to day 13). More precisely, Gmean and corresponding 95% CI of givinostat plasma and urine concentration and givinostat metabolites plasma concentration versus time profiles following single (Day 1) and multiple-dose (Day 5 to Day 13) administration of givinostat are reported using Linear Scale and Semi- Logarithmic Scale. Descriptive statistics of givinostat plasma pharmacokinetic parameters and givinostat metabolites PK parameters following single-dose administration of givinostat (day 1) and following multiple-dose administration of givinostat (Day 13) were calculated. Descriptive statistics of givinostat and its metabolites urinary excretion profile following single-dose administration of givinostat (day 1) and following multipledose administration of givinostat (Day 13) were calculated. Descriptive statistics of givinostat and its metabolites cumulative amount of urinary excretion profile following single-dose administration of givinostat (day 1) and following multiple-dose administration of givinostat (Day 13) were also calculated using linear scales.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date May 24, 2022
Est. primary completion date May 8, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - A subject was considered eligible for the study if he/she fulfilled all the inclusion criteria: 1. Subject's written informed consent obtained prior to any study-related procedure. 2. Male or female subject, =18 and =55 years of age, at the time of signing the informed consent. 3. Body mass index (BMI) of 18.5 to 32.0 kg/m2 inclusive, and body weight =55 kg and =100 kg for females and body weight =60 kg and =110 kg for males. 4. Non-smoker or ex-smoker (i.e. someone who abstained from using tobaccoor nicotine-containing products for at least 3 months prior to Screening). 5. No clinically relevant diseases. 6. No major surgery within 4 weeks prior to dosing. 7. No clinically relevant abnormalities on physical examination. 8. No clinically relevant abnormalities on 12-lead ECG. 9. No clinically relevant abnormalities on clinical laboratory tests. 10. Negative test results for anti-Human Immunodeficiency virus 1 and 2 antibodies (anti-HIV-1Ab and anti-HIV-2Ab), Hepatitis B surface antigen (HBsAg) and anti-Hepatitis C virus antibodies (anti-HCVAb). 11. Female subjects are eligible if they are of non-childbearing potential or agree to use a non-hormonal highly effective contraceptive method from 28 days prior to Screening until at least 90 days after the last study drug administration. Nonchildbearing potential female is defined as: 1. Menopausal, i.e. no menses for = 12 months without an alternative medical cause other than menopause, and a high FSH level. 2. Pre-menopausal female with documented hysterectomy, bilateral salpingectomy and/or bilateral oophorectomy. A non-hormonal effective contraceptive method is defined as: 1. Intrauterine device. 2. Bilateral tubal occlusion. 3. Total abstinence of heterosexual intercourse, in accordance with the lifestyle of the subject. 4. Vasectomized partner, who has received medical assessment of the surgical success, or clinically diagnosed infertile partner. 12. Male subjects who are sexually active with a female partner of childbearing potential (pregnant or non-pregnant) must use contraception (condom) from investigational product administration up to at least 90 days following the last study drug administration. 13. Male subjects must ensure that his non-pregnant female partner of childbearing potential agrees to consistently and correctly use for the same period a highly effective method of contraception. 14. Male subjects must be willing not to donate sperm until 90 days following the last study drug administration. 15. Willingness and capability to comply with the requirements of the study and ability to understand the study procedures and the risks involved. Exclusion Criteria: A subject was excluded from the study if he/she fulfilled any of the exclusion criteria: At Screening 1. Previous use of givinostat. 2. History of anaphylaxis reaction or clinically significant drug hypersensitivity reaction (e.g., angioedema, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, drug-induced hypersensitivity syndrome, druginduced neutropenia). 3. Known history of hypersensitivity and/or allergic reactions to givinostat, histone deacetylases (HDAC) inhibitors or to any excipient in the formulation. 4. History of sorbitol intolerance, sorbitol malabsorption or fructose intolerance. 5. Any medical condition (e.g. gastrointestinal, renal or hepatic, including peptic ulcer, inflammatory bowel disease or pancreatitis) or surgical condition (e.g. cholecystectomy, gastrectomy) that may affect drug pharmacokinetics (absorption, distribution, metabolism or excretion) or subject safety. 6. Systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 60 or over 90 mmHg, or pulse rate lower than 50 or over 100 bpm. 7. QTcF ?450 msec. 8. Subjects with history of cardiac arrhythmias (documented), family history of sudden cardiac death or history of additional risk factors for torsades-depointes (e.g. heart failure, hypokalemia, long QT syndrome). 9. Having an estimated glomerular filtration (eGFR) < 90 mL/min, based on creatinine clearance calculation by the Cockcroft-Gault formula and normalized to an average surface area of 1.73 m2. 10. Any of the following abnormal laboratory test values: 1. Platelet count below the lower limit of the normal range (LLN) 2. Total white blood cells count below the LLN 3. Hemoglobin below the LLN 4. Triglycerides above the upper limit of normal range (ULN) 5. Potassium or magnesium below the LLN 11. Positive urine alcohol, drugs-of-abuse or cotinine screen tests. 12. Positive serum pregnancy test. 13. If woman, she is breast-feeding. 14. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit (i.e. more than 14 units of alcohol per week for males or more than 7 units for females). 15. History of drug abuse within 1 year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs [such as cocaine, phencyclidine (PCP), crack, opioid derivatives including heroin, and amphetamine derivatives] within 1 year prior to screening. 16. Participation in any clinical trial within the previous 2 months. 17. Participation in more than 2 clinical trials within the previous 12 months. 18. Blood donation or significant blood loss (= 450 mL) due to any reason or had plasmapheresis within the previous 2 months. 19. Veins unsuitable for intravenous puncture on either arm. 20. Difficulty in swallowing capsules, tablets or suspensions. 21. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study. At Admission to Treatment Period 22. Any clinically relevant abnormalities on clinical laboratory tests. 23. Positive urine alcohol, drugs-of-abuse or cotinine screen tests. 24. Positive urine pregnancy test. 25. Positive or inconclusive SARS-CoV-2 test prior to admission. 26. Use of prescription or non-prescription medicinal products within the previous 28 days or within 5-half-lives of the medicinal product, whichever is longer. 27. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Givinostat
Drug: ITF2357 Givinostat 10mg/mL Dose: 10mg/mL; Dosage form: oral suspension

Locations

Country Name City State
Portugal Hospital da Prelada, 3rd Floor & East Wing 4th Floor Rua Sarmento de Beires Porto

Sponsors (1)

Lead Sponsor Collaborator
Italfarmaco

Country where clinical trial is conducted

Portugal, 

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma Pharmacokinetic Parameters of givinostat, following multiple-dose administration of givinostat (Day 13): Cmax Cmax is the Maximum Observed Plasma Concentration. The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563.
A total of 48 blood samples were collected as follows:
- 22 blood samples at predose and at the timepoints indicated in the timeframe field after the administration of givinostat (post-dose), on Days 1 (and 13), for the determination of givinostat and its metabolites (ITF2374, ITF2375, ITF2440 and ITF2563) plasma concentrations.
Four (4) blood samples before the morning dose of givinostat on Days 9, 10, 11 and 12, for the determination of pre-dose (Ctrough) plasma concentration of givinostat and its metabolites.
Predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60, 72, 84 and 96 hours post dose and before the morning dose of givinostat on Days 9, 10, 11 and 12
Primary Plasma Pharmacokinetic Parameters of givinostat, following multiple-dose administration of givinostat (Day 13): Tmax Tmax is the Time to Maximum Observed Concentration.The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563.
A total of 48 blood samples were collected as follows:
- 22 blood samples at predose and at the timepoints indicated in the timeframe field after the administration of givinostat (post-dose), on Days 1 (and 13), for the determination of givinostat and its metabolites (ITF2374, ITF2375, ITF2440 and ITF2563) plasma concentrations.
Four (4) blood samples before the morning dose of givinostat on Days 9, 10, 11 and 12, for the determination of pre-dose (Ctrough) plasma concentration of givinostat and its metabolites.
Predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60, 72, 84 and 96 hours post dose and before the morning dose of givinostat on Days 9, 10, 11 and 12
Primary Plasma Pharmacokinetic Parameters of givinostat, following multiple-dose administration of givinostat (Day 13): Ctrough Ctrough is the Pre-dose Plasma Concentration.
The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563.
A total of 48 blood samples were collected as follows:
- 22 blood samples at predose and at the timepoints indicated in the timeframe field after the administration of givinostat (post-dose), on Days 1 (and 13), for the determination of givinostat and its metabolites (ITF2374, ITF2375, ITF2440 and ITF2563) plasma concentrations.
Four (4) blood samples before the morning dose of givinostat on Days 9, 10, 11 and 12, for the determination of pre-dose (Ctrough) plasma concentration of givinostat and its metabolites.
Predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60, 72, 84 and 96 hours post dose and before the morning dose of givinostat on Days 9, 10, 11 and 12
Primary Plasma Pharmacokinetic Parameters of givinostat, following multiple-dose administration of givinostat (Day 13): AUC0-inf. AUC0-inf is the AUC from Time Zero to Infinity.The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563.
A total of 48 blood samples were collected as follows:
- 22 blood samples at predose and at the timepoints indicated in the timeframe field after the administration of givinostat (post-dose), on Days 1 (and 13), for the determination of givinostat and its metabolites (ITF2374, ITF2375, ITF2440 and ITF2563) plasma concentrations.
Four (4) blood samples before the morning dose of givinostat on Days 9, 10, 11 and 12, for the determination of pre-dose (Ctrough) plasma concentration of givinostat and its metabolites.
Predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60, 72, 84 and 96 hours post dose and before the morning dose of givinostat on Days 9, 10, 11 and 12
Primary Plasma Pharmacokinetic Parameters of givinostat, following multiple-dose administration of givinostat (Day 13): AUC0-t. AUC0-t is the AUC from Time Zero to Last Sampling Time with Quantifiable.
The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563.
A total of 48 blood samples were collected as follows:
- 22 blood samples at predose and at the timepoints indicated in the timeframe field after the administration of givinostat (post-dose), on Days 1 (and 13), for the determination of givinostat and its metabolites (ITF2374, ITF2375, ITF2440 and ITF2563) plasma concentrations.
Four (4) blood samples before the morning dose of givinostat on Days 9, 10, 11 and 12, for the determination of pre-dose (Ctrough) plasma concentration of givinostat and its metabolites.Concentrations
Predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60, 72, 84 and 96 hours post dose and before the morning dose of givinostat on Days 9, 10, 11 and 12
Primary Plasma Pharmacokinetic Parameters of givinostat, following multiple-dose administration of givinostat (Day 13): AUC0-t, AUC0-t is the area under the plasma concentration versus time curve. The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563.
A total of 48 blood samples were collected as follows:
- 22 blood samples at predose and at the timepoints indicated in the timeframe field after the administration of givinostat (post-dose), on Days 1 (and 13), for the determination of givinostat and its metabolites (ITF2374, ITF2375, ITF2440 and ITF2563) plasma concentrations.
Four (4) blood samples before the morning dose of givinostat on Days 9, 10, 11 and 12, for the determination of pre-dose (Ctrough) plasma concentration of givinostat and its metabolites.
Predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60, 72, 84 and 96 hours post dose and before the morning dose of givinostat on Days 9, 10, 11 and 12
Primary Plasma Pharmacokinetic Parameters of givinostat, following multiple-dose administration of givinostat (Day 13): %AUCextrap %AUCextrap is the Residual Area or Percentage of Extrapolated Part of AUC0-8. The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563.
A total of 48 blood samples were collected as follows:
- 22 blood samples at predose and at the timepoints indicated in the timeframe field after the administration of givinostat (post-dose), on Days 1 (and 13), for the determination of givinostat and its metabolites (ITF2374, ITF2375, ITF2440 and ITF2563) plasma concentrations.
Four (4) blood samples before the morning dose of givinostat on Days 9, 10, 11 and 12, for the determination of pre-dose (Ctrough) plasma concentration of givinostat and its metabolites.
Predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60, 72, 84 and 96 hours post dose and before the morning dose of givinostat on Days 9, 10, 11 and 12
Primary Plasma Pharmacokinetic Parameters of givinostat, following multiple-dose administration of givinostat (Day 13): ?z ?z is the Apparent Terminal Elimination Rate Constant. The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563.
A total of 48 blood samples were collected as follows:
- 22 blood samples at predose and at the timepoints indicated in the timeframe field after the administration of givinostat (post-dose), on Days 1 (and 13), for the determination of givinostat and its metabolites (ITF2374, ITF2375, ITF2440 and ITF2563) plasma concentrations.
Four (4) blood samples before the morning dose of givinostat on Days 9, 10, 11 and 12, for the determination of pre-dose (Ctrough) plasma concentration of givinostat and its metabolites.
Predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60, 72, 84 and 96 hours post dose and before the morning dose of givinostat on Days 9, 10, 11 and 12
Primary Plasma Pharmacokinetic Parameters of givinostat, following multiple-dose administration of givinostat (Day 13): t1/2 t1/2 is the Apparent Terminal Half-Life.
The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563.
A total of 48 blood samples were collected as follows:
- 22 blood samples at predose and at the timepoints indicated in the timeframe field after the administration of givinostat (post-dose), on Days 1 (and 13), for the determination of givinostat and its metabolites (ITF2374, ITF2375, ITF2440 and ITF2563) plasma concentrations.
Four (4) blood samples before the morning dose of givinostat on Days 9, 10, 11 and 12, for the determination of pre-dose (Ctrough) plasma concentration of givinostat and its metabolites.
Predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60, 72, 84 and 96 hours post dose and before the morning dose of givinostat on Days 9, 10, 11 and 12
Primary Plasma Pharmacokinetic Parameters of givinostat, following multiple-dose administration of givinostat (Day 13): VD/F VD/F is the Apparent volume of distribution. The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563.
A total of 48 blood samples were collected as follows:
- 22 blood samples at predose and at the timepoints indicated in the timeframe field after the administration of givinostat (post-dose), on Days 1 (and 13), for the determination of givinostat and its metabolites (ITF2374, ITF2375, ITF2440 and ITF2563) plasma concentrations.
Four (4) blood samples before the morning dose of givinostat on Days 9, 10, 11 and 12, for the determination of pre-dose (Ctrough) plasma concentration of givinostat and its metabolites.
Predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60, 72, 84 and 96 hours post dose and before the morning dose of givinostat on Days 9, 10, 11 and 12
Primary Plasma Pharmacokinetic Parameters of givinostat, following multiple-dose administration of givinostat (Day 13): Cmax,ss Cmax,ss is the Maximum Observed Plasma Concentration at steady state. The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563.
A total of 48 blood samples were collected as follows:
- 22 blood samples at predose and at the timepoints indicated in the timeframe field after the administration of givinostat (post-dose), on Days 1 (and 13), for the determination of givinostat and its metabolites (ITF2374, ITF2375, ITF2440 and ITF2563) plasma concentrations.
Four (4) blood samples before the morning dose of givinostat on Days 9, 10, 11 and 12, for the determination of pre-dose (Ctrough) plasma concentration of givinostat and its metabolites.
Predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60, 72, 84 and 96 hours post dose and before the morning dose of givinostat on Days 9, 10, 11 and 12
Primary Plasma Pharmacokinetic Parameters of givinostat, following multiple-dose administration of givinostat (Day 13): Tmax,ss Tmax,ss is the Time of occurrence of Cmax,ss. The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563.
A total of 48 blood samples were collected as follows:
- 22 blood samples at predose and at the timepoints indicated in the timeframe field after the administration of givinostat (post-dose), on Days 1 (and 13), for the determination of givinostat and its metabolites (ITF2374, ITF2375, ITF2440 and ITF2563) plasma concentrations.
Four (4) blood samples before the morning dose of givinostat on Days 9, 10, 11 and 12, for the determination of pre-dose (Ctrough) plasma concentration of givinostat and its metabolites.
Predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60, 72, 84 and 96 hours post dose and before the morning dose of givinostat on Days 9, 10, 11 and 12
Primary Plasma Pharmacokinetic Parameters of givinostat, following multiple-dose administration of givinostat (Day 13): AUC0-t,ss AUC0-t,ss is the AUC during a Dosing Interval at steady state. The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563.
A total of 48 blood samples were collected as follows:
- 22 blood samples at predose and at the timepoints indicated in the timeframe field after the administration of givinostat (post-dose), on Days 1 (and 13), for the determination of givinostat and its metabolites (ITF2374, ITF2375, ITF2440 and ITF2563) plasma concentrations.
Four (4) blood samples before the morning dose of givinostat on Days 9, 10, 11 and 12, for the determination of pre-dose (Ctrough) plasma concentration of givinostat and its metabolites.
Predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60, 72, 84 and 96 hours post dose and before the morning dose of givinostat on Days 9, 10, 11 and 12
Primary Plasma Pharmacokinetic Parameters of givinostat, following multiple-dose administration of givinostat (Day 13): CLss/F. CLss/F is the Apparent total body clearance at steady state. The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563.
A total of 48 blood samples were collected as follows:
- 22 blood samples at predose and at the timepoints indicated in the timeframe field after the administration of givinostat (post-dose), on Days 1 (and 13), for the determination of givinostat and its metabolites (ITF2374, ITF2375, ITF2440 and ITF2563) plasma concentrations.
Four (4) blood samples before the morning dose of givinostat on Days 9, 10, 11 and 12, for the determination of pre-dose (Ctrough) plasma concentration of givinostat and its metabolites.
Predose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 60, 72, 84 and 96 hours post dose and before the morning dose of givinostat on Days 9, 10, 11 and 12
Primary Urinary Pharmacokinetic Parameters of givinostat following first dose (day 1) and after multiple doses of givinostat (Day 13): Rmax. Rmax is the Maximum urinary excretion rate. The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563. Urine was collected on Day -1 (baseline) and in the following intervals, on Days 1 and 13, for the determination of the amounts of givinostat and its metabolites excreted in urine at the timepoints indicated in the timeframe field. Predose and 13, 0-12, 12-24, 24-36, 36-48, 48-72 and 72-96 hours post-dose.
Primary Urinary Pharmacokinetic Parameters of givinostat following first dose (day 1) and after multiple doses of givinostat (Day 13): tumax tumax is the Time to Rmax. The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563.
Urine was collected on Day -1 (baseline) and in the following intervals, on Days 1 and 13, for the determination of the amounts of givinostat and its metabolites excreted in urine at the timepoints indicated in the timeframe field.
Predose and 13, 0-12, 12-24, 24-36, 36-48, 48-72 and 72-96 hours post-dose.
Primary Urinary Pharmacokinetic Parameters of givinostat following first dose (day 1) and after multiple doses of givinostat (Day 13): AmtCUM AmtCUM is the Cumulative amount of drug excreted in urine.
The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563. Urine was collected on Day -1 (baseline) and in the following intervals, on Days 1 and 13, for the determination of the amounts of givinostat and its metabolites excreted in urine at the timepoints indicated in the timeframe field.
Predose and 13, 0-12, 12-24, 24-36, 36-48, 48-72 and 72-96 hours post-dose.
Primary Urinary Pharmacokinetic Parameters of givinostat following first dose (day 1) and after multiple doses of givinostat (Day 13): AURC0-t AURC0-t is the Area under the urine excretion curve from time zero to last measurable observed excretion rate. The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563. Urine was collected on Day -1 (baseline) and in the following intervals, on Days 1 and 13, for the determination of the amounts of givinostat and its metabolites excreted in urine at the timepoints indicated in the timeframe field. Predose and 13, 0-12, 12-24, 24-36, 36-48, 48-72 and 72-96 hours post-dose.
Primary Urinary Pharmacokinetic Parameters of givinostat following first dose (day 1) and after multiple doses of givinostat (Day 13): REC% REC% is the Percentage of drug recovered in urine. The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563. Urine was collected on Day -1 (baseline) and in the following intervals, on Days 1 and 13, for the determination of the amounts of givinostat and its metabolites excreted in urine at the timepoints indicated in the timeframe field. Predose and 13, 0-12, 12-24, 24-36, 36-48, 48-72 and 72-96 hours post-dose.
Primary Urinary Pharmacokinetic Parameters of givinostat following first dose (day 1) and after multiple doses of givinostat (Day 13): CLR/F The givinostat metabolites were: ITF2374, ITF2375, ITF2440, ITF2563. Urine was collected on Day -1 (baseline) and in the following intervals, on Days 1 and 13, for the determination of the amounts of givinostat and its metabolites excreted in urine at the timepoints indicated in the timeframe field. Predose and 13, 0-12, 12-24, 24-36, 36-48, 48-72 and 72-96 hours post-dose.
Secondary Incidence and severity of Adverse Events An AE was considered as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily imply a causal relationship with this treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The period of observation for the collection of medical occurrences extended from the time when the subject gave Informed Consent until the follow-up visit. Throughout the study, until 10-14 days after EoS (day 17), i.e. till day 27-31
See also
  Status Clinical Trial Phase
Completed NCT05574374 - Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects Phase 1
Completed NCT04557397 - Fruquintinib CYP3A Inhibitor and Inducer Study Phase 1
Completed NCT06031454 - Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin Phase 1
Completed NCT05137600 - A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects Phase 1
Recruiting NCT06119958 - Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects Phase 1
Active, not recruiting NCT05812404 - Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects Phase 1
Completed NCT04606537 - Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects Phase 1
Completed NCT04939467 - Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Completed NCT04542252 - Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects Phase 1
Enrolling by invitation NCT06037564 - B-free Multistage Trial Phase 4
Completed NCT05123820 - Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470 Phase 1
Recruiting NCT04840862 - Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor Phase 4
Completed NCT04814498 - Drug-Drug Interaction (DDI) Study in Healthy Volunteers Phase 1
Completed NCT01350921 - Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers Phase 1
Completed NCT03103568 - A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers Phase 1
Completed NCT04840641 - Flucloxacillin as an Inducer of CYP-enzymes Phase 1
Completed NCT05304845 - Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects Phase 1
Completed NCT05845567 - The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2) Phase 1
Completed NCT04776499 - Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers Phase 1
Completed NCT03909529 - Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug) Phase 1